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There have been five overlapping stages in the growth of structural biology. The ancients learned much about animals and plants through comparative anatomy. A systematic study of animal anatomy through dissection began in the 16th century. Microscopic anatomy began in the mid17th century, and by the early 1900's there were detailed descriptions of a wide diversity of organs and organisms. 1940--1970 saw a comparable flowering of knowledge about cellular fine structure and macromolecular assembly, thanks in part to the electron microscope. The details of macromolecular structure were, however, largely invisible without crystallography, and the fruits of this technology are still ripening.
Each of the above stages in the development of "anatomy" has depended on a new method or approach whose availability led to rapid growth in structural information at a novel level of size or detail. An analogous situation now pertains to determination of DNA sequence. While the technology for sequencing proteins and nucleic acids has been available for decades, recent improvements have made it possible to learn the primary structure of DNA comparatively quickly. As a result, there has been a huge increase in the number of labs that are sequencing DNA and an almost incredible increase in the rate of sequence acquisition. The availability of computers fast enough to deal expeditiously with all the resulting data has permitted efficient analyses and comparisons of DNA sequences and of the polypeptides predicted from them, so the flow of information from acquisition to utilization for biological comparisons has become both rapid and objective. The resulting catalogues of genes and gene products are facilitating a new version of all the discriminations that have traditionally made anatomical information useful; clearly the sixth age of anatomy is at hand.
During each stage in the development of structural biology, the practitioners have been delighted in their new view of nature. Others in the scientific community have generally been less enthusiastic, finding structure itself of little interest unless it can be related to function. When this goal has been achieved, then anatomical detail has been invaluable for elucidating biological mechanisms. For example, a mitochondrion makes no sense until its enzymes are localized relative to its membranes; a catalytic mechanism is usually revealed by comparing the structure of its active site with different substrate analogues bound.
When study of the human genome was introduced essentially as a grand project in anatomy, many of us were highly skeptical of its value. Doubt arose in part because sequencing for its own sake seemed so mindless, in part because the human genome seemed likely to contain a large amount of DNA whose sequence would convey little information, and in part because it seemed that allocations to support this work would likely divert resources from the already competitive RO1 grants that support more conventional biomedical science. Several things have happened, however, to change the face of things.
Genome Research Has Been Organized in Two Useful Hierarchies
Rather than choosing a few pieces of the human DNA and beginning to sequence, genome researchers have organized their work in two important ways: (1) they have focused on model organisms with small genomes where there was already sufficient genetic and molecular information to give context and meaning to sequence data; and (2) genome work on each organism has begun with the generation of physical maps, so sequence information can be related to genetic maps and studies of mutant phenotype.
One of the first major sequencing efforts has been with the yeast Saccharomyces cerevisiae, whose genome was known to be small (~12.5 megabases [Mb]). Many yeast genes had already been identified by mutation, and several regions of this genome had been analyzed by saturation mutagenesis, which identifies most genetically recognizable loci. The frequency and size of intervening and spacer DNA sequences were known to be small, and physical maps of the genome had already been constructed. There were also methods for manipulating this genome experimentally, e.g., gene replacement by homologous recombination, so one could anticipate that sequence information could be related to the functional consequences of mutation. When systematic sequencing began, the 16 S. cerevisiae chromosomes were undertaken by several yeast labs throughout the world. As of October 1995, over three-quarters of the (11) and completion of the project is expected by the beginning of 1996. For detailed information about the current state of work on this and other genomes, please see the Internet addresses given in Table I . Genome research on more complex model organisms has again begun with the formation of detailed physical maps and limited genomic sequencing. For the nematode, Caenorhabditis elegans (genome size ~100 Mb), a collection of "cosmid" clones has been constructed, each of which carries tens of kilobases (kb) of exogenous DNA. Many of these sequences are from contiguous loci, yielding an ordered library that covers much of the genome. There is now a C. elegans genomic library in yeast artificial chromosomes (YACS) as well; each of these clones contains hundreds of kb of DNA, so the number needed to cover a larger genome is manageable (8) . Meanwhile, DNA sequencing has been going on in two centers, and the rate of new finished sequence (six determinations to minimize the chances of error) now exceeds one cosmid/day (7). Completion of this genome is expected by the end of 1998 (Table I) .
For model organisms with larger genomes, like fruit flies (genome 1.5 x that of C. elegans) and mice (30 x the nematode), the above strategy is being employed in an expanded form. Both YAC and cosmid libraries are now available to help map genes to specific pieces of DNA. Indeed, much of the recent work on the human genome has been focused not on DNA sequencing, but on detailed chromosomal mapping. Microsatellites (short segments of repetitive DNA) are being used to identify unique molecular markers with better than 1 centimorgan resolution, and physical maps are being generated with sequence-tagged sites (STSs) on YAC and cosmid clones. This work has significantly refined results from the classic methods of cytogenetics, like Q or G banding, as well as older molecular mapping methods, like restriction fragment length polymorphisms. The result is both a useful map of genes related to human diseases and tools that will be necessary for molecular studies of particular chromosomal regions. Systematic sequencing of the human genome is just now getting underway (Table I) .
Sequence Data Are Telling Us Surprising Things about

Genome Structures and Functions
Information from S. cerevisiae and C. elegans is already telling us interesting things about genome structure and organization. In addition to the obvious features, like the number of genes in a given amount of DNA, the statistics of gene size, and the distribution of genes among major families defined by sequence, things are coming to light that few would have predicted. The sequences from regions subjected to saturation mutagenesis have revealed many more genes than were found in searches for mutants with phenotypes. For example, genetic estimates predicted ~3,000
essential genes in C. elegans (3) , but estimates from genome sequence suggest ~13,000 (10) . Presumably, the inactivation of the additional genes by mutation is either irrelevant for growth as we assess it in the laboratory or is "covered" by the functions of other, unmutated genes. The work has also revealed novel features of genome organization: there are genes within introns, genes that appear to encode giant proteins, and clusters of genes with unknown functions (12) . While more than half the genes so far discovered by sequencing are of unknown function, ~40% of the genes from C. elegans (7) , ~55% from S. cerevisiae (11) , and 58% from the prokaryote, H. influenzae (6) encode proteins whose sequences are similar to the products of genes already identified in other organisms. Clearly, there is much still to do in tracking down and analyzing unknown genes, but it is encouraging that so much sequence information can already be understood in some functional context and related to processes that are under study elsewhere. Large scale studies of gene sequences have also opened up a new approach to genetic comparisons. Many genes from humans and other organisms have been partially characterized by sequencing only a small part of a eDNA to yield an "expressed sequence tag" (EST). 1 These have been organized in data bases of ESTs (dbEST), and the catalogues of these sequences are expanding by several hundred sequences/day (Table I ). When the sequences of genes identified by mutation are compared with those in the dbESTs, it has sometimes been possible to find a significant similarity, thereby identifying a mammalian gene that corresponds to a gene already characterized in a simpler organism, like a yeast (9) . Homologous sequences have now been identified in model organisms for most of the N50 human diseases genes that have been mapped by positional cloning (1, 2, 4, and Table I ). There are two important consequences of these developments: (a) the detailed analysis of gene structure and function, which is comparatively cheap and efficient in model organisms, is likely to be of direct benefit in understanding complex processes and pathologies in higher eukaryotes; and (b) it will be possible to study many human diseases in organisms whose experimental manipulation is not ethically offensive.
The Conservation of Some Genes That Control Complex Functions Is Strong Enough That Currently Mysterious Aspects of Organismic Biology Are Likely to Profit from Genome Work
The homeotic loci of Drosophila are widely known to play key roles in the hierarchical regulation of gene expression. Studies of homologous sequences in organisms with apparently different body plans have more recently suggested that genome structure is related to the processes that regulate development. For example, the genomic order of the homeotic "HOX" genes in several vertebrates is correlated with both the temporal and the positional order of their expression (for a review see reference 5). This case suggests that there may be important properties of genomic organization that are still beyond our grasp. While sequence information is unlikely to be sufficient for elucidating these properties, it is almost certainly a prerequisite. There may be a parallel between the way information about specific genes is currently linking yeast and mammalian cell biology, and the way analogous information about higher order genome structure will illuminate developmental biology.
The Investment in Genome Structure by Labs That Are Set Up to Sequence Efficiently May Expedite Cell Biological Research and Save Money
Many cell biologists who began their careers as microscopists or biochemists are now engaged in "molecular biology," meaning that they are cloning and sequencing the genes that encode proteins essential for the cellular processes they study. This makes sense because we have all witnessed the power of recombinant DNA technology for expediting research on proteins that are present in amounts too small for practical biochemistry. Moreover, the use of antisense RNA, gene disruptions, and transfection with mutant DNA encoding proteins with dominant negative phenotypes are now important companions to antibody perturbations and pharmacology for the study of complex processes in organisms without powerful genetics. The result is that "cell biology" labs all over the world are now spending significant time and resources cloning, mapping, sequencing, and mutating DNA, when what they want to be doing (and do best) is studying the behavior of gene products. This work is often called "reagent construction," and it is now common to spend years assembling the DNA clones, mutants, protein fragments, and antibodies necessary to do a key cell biological experiment. For students of cell biology, it is almost a modern Rite of Passage to get a clone and sequence it, etc., in preparation for the originally intended experiment. Lamentably, this is mostly mundane work in which daily tasks bear little relation to the biological problems selected for study. When one sees bright and energetic cell biologists dulling their enthusiasm on kilobases of DNA sequence in order to get the background information necessary to make the tools they need, one can't help but think that there must be a better way.
Taken together these observations have made us supporters of genome research. The investment of a reasonable fraction of our community's resources in accumulating information about DNA sequence and organization is likely to pay big dividends, not only in knowledge of genome structure but in the saving of countless hours of molecular drudge work. A well set up sequencing lab can produce ~2 kb of finished sequence per worker per day, while labs that are sequencing by hand are doing well if they get 1/10th that amount. Moreover, the cost per base drops by ~10-fold when the work is done in a lab with proper equipment and experience. The current rate of sequence collection will probably increase as technology improves, implying that we should continue with significant investments in the study of genome structure for the near future. While those of us doing experiments may resent the expenditure of money that might have helped us to stay funded, the resulting information will almost certainly be worth the investment, and the approach will probably save money.
Even with All This Success, There Are Problems That
Must be Addressed by Our Scientific Community
Enthusiasm for genome research does, however, lead to three problems that our community must address: (1) since resources are limited, the dollars spent on genome research must be consistent with our current funding constraints. The 1995 investment in extramural research by the National Center for Human Genome Research (NCHGR) was ~$114 million, while the Departments of Energy and of Agriculture spent ~$69.5 and $3.8 million, respectively, on genome work. The Small Business Administration spent $3 million, and comparatively small sums that are hard to determine came from other Institutes at the National Institutes of Health (NIH) and from the National Science Foundation. These investments in aggregate are small relative to the whole NIH budget (~$12 billion for 1995), but they are significant compared with the budget of the National Institute for General Medical Sciences (just over $900 million), the agency upon which many of us rely. Given the importance of genome work and given the investments by other institutes and agencies in basic biomedical research, broadly defined, the current balance seems to us reasonable, but a greater investment in genome work would tip the balance.
(2) The results from sequencing are first available to the sequencers themselves. With genome labs funded by in-dustries, as well as the government, it is critically important to maximize the free and rapid flow of sequence information into the public domain, otherwise knowledge will be either wasted or improperly used. Some sequencing labs have been models of efficiency in making their data available, but others have not. The NCHGR has stipulated that sequence data from the labs they fund must be made public within 6 mos, but some labs in foreign countries are slower than that, and some industries attach strings to sequences they share. We believe that efforts should be made to minimize the time to public access in order to maximize the rate at which good science can be done. Moreover, the push by both individuals and companies to profit from sequences and/or to restrict their use is a problematic trend that will take some years to sort out in the courts. In the interim we must work to minimize the chances that profit motives retard scientific progress.
(3) In the future, sequencing labs will certainly provide important information, e.g., the genome structures for model organisms, humans, and important pathogens, as well as the mapping of human disease genes. With such longevity, however, sequencing labs may tend to become entrenched, so their lifetimes exceed their utility. It is impossible to say now when enough genome work will have been done, but there is an obvious analogy with a learning curve. Sequencing centers may want to go on from human to aardvark, caiman, and dodo, expanding our knowledge of evolution, phylogeny, and extinction. The community of biologists will have to recognize when new knowledge from new sequences has begun to plateau and rein in the rate of spending. Sequencing programs must be structured so they can shrink as their value diminishes, giving way to more experimentally oriented biology.
That said, it is clear that future biologists will be working in an environment defined by a wondrous wealth of information about genome structure. It is mind boggling to think of the ways in which our experimental lives will be changed as a result. No field of biology will be untouched, and a whole new generation of experimental approaches will likely emerge to help justify the investments that are now being made in sequence acquisition and analysis.
